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ABSTRACT
Background
RPE65 is specifically expressed in the retinal pigment epithelium and is essential for the
recycling of 11-cis-retinal, the chromophore of rod and cone opsins. In humans, mutations in
RPE65 lead to Leber congenital amaurosis or early-onset retinal dystrophy, a severe form of
retinitis pigmentosa. The proof of feasibility of gene therapy for RPE65 deficiency has already
been established in a dog model of Leber congenital amaurosis, but rescue of the cone
function, although crucial for human high-acuity vision, has never been strictly proven. In Rpe65
knockout mice, photoreceptors show a drastically reduced light sensitivity and are subject to
degeneration, the cone photoreceptors being lost at early stages of the disease. In the present
study, we address the question of whether application of a lentiviral vector expressing the
Rpe65 mouse cDNA prevents cone degeneration and restores cone function in Rpe65 knockout
mice.
Methods and Findings
Subretinal injection of the vector in Rpe65-deficient mice led to sustained expression of
Rpe65 in the retinal pigment epithelium. Electroretinogram recordings showed that Rpe65 gene
transfer restored retinal function to a near-normal pattern. We performed histological analyses
using cone-specific markers and demonstrated that Rpe65 gene transfer completely prevented
cone degeneration until at least four months, an age at which almost all cones have
degenerated in the untreated Rpe65-deficient mouse. We established an algorithm that allows
prediction of the cone-rescue area as a function of transgene expression, which should be a
useful tool for future clinical trials. Finally, in mice deficient for both RPE65 and rod transducin,
Rpe65 gene transfer restored cone function when applied at an early stage of the disease.
Conclusions
By demonstrating that lentivirus-mediated Rpe65 gene transfer protects and restores the
function of cones in the Rpe65
 /  mouse, this study reinforces the therapeutic value of gene
therapy for RPE65 deficiencies, suggests a cone-preserving treatment for the retina, and
evaluates a potentially effective viral vector for this purpose.
The Editors’ Summary of this article follows the references.
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The neuroretina is composed of several cell layers in which
light stimuli are converted into an electric signal by the
photoreceptors. This conversion process takes place in the
visual pigment of the photoreceptors, which is composed of
opsin, a protein component, and 11-cis-retinal, a vitamin A
chromophore. Absorption of light triggers isomerisation of
the chromophore into all-trans-retinal and conformational
change of the opsin. Upon this activation, the phototrans-
duction cascade is initiated, which ﬁnally results in the
generation of the electric signal. To regain light sensitivity,
all-trans-retinal must be re-isomerised to 11-cis-retinal. This
regeneration requires transport of the all-trans-retinal to the
adjacent retinal pigment epithelium (RPE), where a number
of enzymatic reactions are involved in the re-isomerisation to
11-cis-retinal, before transport of the chromophore back to
the photoreceptors [1]. The pigment epithelial protein RPE65
is essential for this process [2] because it catalyses the re-
isomerisation of the all-trans-retinoid into the 11-cis form [3–
5]. In agreement with this essential function, mice deﬁcient
for RPE65 have strongly reduced retinal function [2,6]. In
humans, RPE65 mutations cause a form of early-onset retinal
dystrophy termed Leber congenital amaurosis [7–9], which
leads to early blindness.
The ability to efﬁciently target RPE cells with viral vectors
has led to the proposal that RPE65 deﬁciencies are good
candidates for gene therapy protocols [10,11]. In 2001, a study
by Acland et al. [12] revealed the clinical potential of Rpe65
gene transfer. In this study, the treatment of RPE65-deﬁcient
dogs by intraocular delivery of a recombinant adeno-
associated virus (rAAV) encoding canine Rpe65 partially
rescued retinal function and restored vision. Furthermore,
long-term follow-up of the treated dogs showed that the
visual recovery was stable for more than three years without
adverse effects [13]. A second study, by Narfstro ¨m et al. in
2003 [14], using the same animal model treated with a rAAV-
encoding canine Rpe65 also demonstrated a long-term
improvement of the visual function up to three years
postinjection, associated with a clear improvement in a
behavioural tests conducted in both day and night vision
[14,15]. As a consequence of these results, two clinical trials
involving rAAV-mediated RPE65 gene transfer were pro-
posed in 2004 in the US, the ﬁrst being accepted while the
second is still under review (NIH GeMCRIS, http://www.
gemcris.od.nih.gov/; protocol numbers 0410–677 and 0510–
740).
It is important, however, to continue to document the
effectiveness of RPE65 gene transfer in animal models,
especially in light of the results obtained recently after
rAAV-mediated gene transfer of RPE65 in the Rpe65 knock-
out mouse (Rpe65
 / ): Gene transfer was effective when
administered in utero, but treatment of adult mice led to
only limited improvement of retinal function [16,17]. There-
fore, the timing of gene therapy seems to be crucial for the
outcome. This is particularly true when aiming at cone vision
rescue, which is of prime importance for human patients.
Interestingly, cone function is lost in Rpe65
 /  mice [6] due to
early-onset degeneration of these cells [18,19], and Chen et al.
[20] demonstrated recently that adenoviral delivery of Rpe65
in Rpe65
  /  mice restores isomerohydrolase activity and
prevents, to a certain extent, early cone loss, although this
latter study did not examine the cone function. rAAV-
mediated Rpe65 gene transfer can also moderately increase
cone cell survival, but its effect on the function of these cells
remains unclear [17]. Thus, RPE65 seems essential for cones,
but the effect of Rpe65 gene transfer on their survival and
function remains to be elucidated.
Most of the work published to date in the ﬁeld of RPE65
gene transfer involved the use of rAAV vectors. These vectors
efﬁciently target retinal cells, and in particular RPE and
photoreceptors when they are injected in the subretinal space
[21–23]. Moreover, the use of different viral serotypes allows
the targeting of both types of cells or the RPE alone [10]. The
cloning capacity of rAAV vectors is, however, limited to 4 kb,
which hampers the use of large transgenes—for instance
ABCA4, the gene mutated in Stargardt disease. In contrast,
lentiviral vectors appear as an attractive alternative to rAAV
for gene therapy protocols targeting RPE cells: The lentiviral
vector has a cloning capacity of up to 10 kb, causes a weak or
absent inﬂammatory response, and expresses transgenes
rapidly. Most importantly, the lentiviral vector transduces
RPE cells with high efﬁciency [10,24–27], making of it an ideal
candidate for Rpe65 gene transfer.
For the present study, we used Rpe65
 /  mice to analyze the
therapeutic effect of lentivirus-mediated gene transfer on
survival and function of the affected retinal cells. As cone
impairment and degeneration progress rapidly in Rpe65
 / 
mice, we performed a detailed analysis of the therapeutic
effect on this photoreceptor subtype. We also used a double-
knockout mouse strain modelling RPE65 deﬁciency on a pure
cone function background to study the effect of gene transfer
on cone function.
Methods
Construction and Production of Lentiviral Vectors
The lentiviral plasmids used in his study were derived from
the pLOX-GFP plasmid [28], which contains the central
polypurine tract and central termination sequence (cPPT/
CTS [29]) and the woodchuck hepatitis virus post-transcrip-
tional regulatory element (WPRE [30]) downstream of the
transgene. To construct the control vector encoding GFP, the
PGK-GFP expression cassette was excised from the pLOX-
GFP plasmid using ClaI (blunted) and BamHI sites, and
replaced by the R0.8-GFP cassette previously extracted by
KpnI (blunted) and BamHI digestion from the pRPE0.8-GFP
plasmid [13,31]. The plasmid encoding Rpe65 was then
generated by insertion of RPE65 mouse cDNA in place of
the GFP ORF in the control plasmid using BamHI and XhoI
sites.
Recombinant lentiviral particles were produced by tran-
sient transfection of 293T cells as previously described
[27,28]. Viral supernatants were concentrated by ultracen-
trifugation at 70,000 g for 90 min at 4 8C. Finally, to achieve a
1,000-fold concentration of the initial supernatant, viral
pellets were resuspended in a minimal of volume of PBS
containing 10 mg/ml BSA. Aliquots of 5–10 ll were then
stored at  70 8C until further use. Total particle concen-
tration of the viral stocks was estimated by quantiﬁcation of
the p24 capsid protein using RETRO-TEK HIV-1 p24 Antigen
ELISA kit (ZeptoMetrix, Buffalo, New York, United States)
according to the manufacturer’s instructions. In addition,
infectious titres of the Hlox-R0.8-GFP vector were quantiﬁed
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active. Brieﬂy, 293T cells were seeded on 12-well plates and
infected by serial dilutions of the vector stocks. On day 4
postinfection, cells were harvested, dissociated, and ﬁxed for
15 min in 4% paraformaldehyde in PBS. The infectious titres
were deduced from the percentage of GFP-expressing cells
estimated by ﬂow cytometry on a FACSCalibur (Becton
Dickinson, Franklin Lakes, New Jersey, United States).
Infectious titres were always in the range of 3 transducing
units per pg of p24 protein.
Animals and Surgical Procedures
Animals were handled in accordance with the statement of
the ‘‘Animals in Research Committee’’ of the Association for
Research in Vision and Ophthalmology (Rockville, Maryland,
United States), and protocols were approved by the local
institutional committee (Service ve ´te ´rinaire du canton de
Vaud, Lausanne, Switzerland). Mice were kept at 22 8C under
a 12 h light–12 h dark cycle with lights on at 7 A.M., and were
fed ad libitum. Rpe65
 /  mice were obtained from Dr. T. M.
Redmond [2], and Rpe65
 / /Gnat1a
 /  double knockout mice
were described previously [32].
Before administration of lentiviral vectors, mice were
transferred to a level 2 conﬁnement room. For intravitreal
injection at postnatal day 5 (P5), mouse pups were anaes-
thetized by volatile anaesthesia (2%–3% isoﬂurane with O2 at
a rate of 800 ml/min). A horizontal incision was made on the
superior eyelid to access the eye. A 34-gauge bevelled needle
mounted on a 5 ll syringe (Hamilton, Bonaduz, Switzerland)
was introduced in the vitreal cavity through the dorsal pole of
the sclera, without touching the lens. 1 ll of viral suspension
diluted in PBS containing 1% BSA was injected into the
vitreous, and the needle was left in place for additional 30 s.
Mouse pups were then returned to their mothers after they
regained consciousness. For subretinal injection during
adulthood, the mice were anesthetized by volatile anaesthesia
(1.5%–3% isoﬂurane with O2 at a rate of 800 ml/min). The
superior eyelid was maintained open by traction using a
suture wire. The eye globe was then immobilized by two
suture wires inserted respectively in nasal and temporal
positions in the conjunctiva at the proximity of the limb.
Using ﬁne ophthalmic scissors, the conjunctiva of the dorsal
pole was dissected, and the sclera/choroid layers were
punctured with an ophthalmic lancet. A 34-gauge bevelled
needle mounted on a 5 ll syringe was then tangentially
inserted into this hole to reach the posterior temporal part of
the subretinal space. 1.5 ll of viral suspension was injected to
create a subretinal bleb, and the needle was left in place 30 s
before withdrawal.
ERG
ERG recordings were performed on site at Jules Gonin Eye
Hospital (Lausanne, Switzerland). For scotopic conditions,
mice were dark-adapted overnight. Subsequent procedures
were undertaken under dim red light unless otherwise
speciﬁed. Mice were anaesthetized with a mixture of ket-
amine (100 mg/kg) and xylazine (15 mg/kg), and pupils were
dilated by topical administration of 0.5% tropicamid
(Novartis Pharma, Bern, Switzerland). Mice were then
positioned on a heated platform to prevent a drop in body
temperature. A reference electrode and a ground electrode
adapted from 30-gauge needles were inserted below the skin
of, respectively, the scalp and the back of the mouse.
Recording electrodes made of thin silver wires were put in
contact with the surface of the cornea, which was then
covered with a carboxymethylcellulose sodium solution
(Celluvisc, Allergan, Irvine, California, United States) to
prevent drying of the cornea and to ensure maximal contact
with the electrodes. The mouse was placed in the centre of a
Ganzfeld stimulator from a Multiliner Vision apparatus
(Jaeger/Toennies, Ho ¨chberg, Germany) adapted for examina-
tion of rodents, and placement of the electrodes was
corrected until the impedance level dropped below 10 kOhm.
The corneal ERG was then recorded in scotopic conditions in
response to single ﬂashes of white light of the following
intensities: 1310
 4,1310
 3,1310
 2,3310
 2,1310
 1,33
10
 1, 1, 3, 10, and 25 candelas (cd) s/m
2, generated by a
stroboscopic light located in the upper part of the Ganzfeld
stimulator. For the photopic ERG, the mice were left in the
Ganzfeld stimulator where they were adapted for 10 min to a
white light of 30 cd/m
2. Photopic responses were then
recorded in response to single ﬂashes ranging from 10 
2 to
25 cd s/m
2, in the same illumination conditions. For each
stimulus intensity, ten to 15 traces were averaged. Amplitude
of the a-wave was deﬁned as the difference between the
baseline level at the time of stimulation and the peak of the a-
wave. Amplitude of the b-wave was deﬁned as the difference
between the peak of the b-wave and the peak of the a-wave (or
the baseline level when the a-wave was not detectable).
Amplitudes are expressed in lV. At the end of the
examination, the eyes were covered with Viscotears (Novartis
Pharma), and the mice were kept under surveillance until
they regained consciousness.
Histology
Tissue processing. After mice were sacriﬁced, the eyes were
enucleated, a hole was created through the cornea, and the
eyes were ﬁxed for 1 h in 4% paraformaldehyde in PBS. After
overnight incubation in 25% sucrose, the eyes were embed-
ded in albumin from hen egg white (Fluka, Buchs, Switzer-
land) and cut in 14 lm sections using a cryostat. Sections were
collected on six serial slides for each eye allowing multiple
labelling throughout the entire eye for each slide.
Immunolabelling. For immunohistological analysis, the
slides were blocked for at least 1 h at room temperature in
PBS with 10% normal goat serum (Dako, Zug, Switzerland)
and 0.2% Triton X-100. Most of the time the primary and
secondary antibodies were incubated in PBS with 2% normal
goat serum and 0.2% Triton. Mouse monoclonal anti-RPE65
(Abcam, Cambridge, United Kingdom) was incubated over-
night at room temperature at 1:1,000, while rabbit polyclonal
anti-RPE65 (pin5 [33]) was incubated overnight at 4 8Ca t
1:500. Rabbit polyclonal anti-GFP (Abcam) was incubated
overnight at room temperature at 1:2,000. Peanut agglutinin
lectin (PNA) labelling was performed using PNA linked to
TRITC (Sigma, Buchs, Switzerland) diluted at 1:1,000 and
incubated overnight at 4 8C. Rabbit polyclonal anti-GNAT2
(Santa Cruz Biochemicals, Santa Cruz, California, United
States) was incubated overnight at room temperature at
1:100, anti-S-opsin (Santa Cruz Biochemicals) and anti-MWL
(Chemicon, Temecula, California, United States) overnight at
4 8C at 1:1,000. Secondary antibodies were goat anti-rabbit
linked to FITC (1:100, Jackson Immunoresearch, Westgrove,
Pennsylvania, United States) or Cy3 (1:500, Jackson Immu-
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Molecular Probes, Eugene, Oregon, United States) were
incubated 1 h at room temperature. For immunolabelling
using the anti-S-opsin, horse serum (Jackson Immunore-
search) and anti-goat-Cy3 (1:1,000; Jackson Immunoresearch)
were used. Before examination, sections were counterstained
with DAPI (Molecular Probes) and mounted under coverslips
with Mowiol 4–88 Reagent (VWR International AG, Lucerne,
Switzerland).
Quantiﬁcation. Sections were analyzed on a BX60 micro-
scope equipped for epiﬂuorescence (Olympus Suisse SA,
Aigle, Switzerland) and coupled to the analySIS 3.0 software
(Soft Imaging System, Munster, Germany). For quantiﬁcation
of the transduced area, images of the whole area expressing
the transgenes were digitized on serial sections separated by
84 lm, the length of the transduced part of the RPE was
calculated with the analySIS software, and the area between
each section was deduced by multiplication of this length by
the intersection distance. To quantify the number of cells
positive for PNA, GNAT2, and M/L- and S-opsin, we chose for
each eye the section that cut the optic nerve in the middle
and was thus the most central. We then counted throughout
the retina of this section the number of outer segments that
stained positive.
Statistical Analysis
Statistical analyses of the ERGs were done using StatView
5.0 software. Histological counting of cone markers was
analyzed by one-way ANOVA to determine the statistical
signiﬁcance between the different groups (LV-RPE65 treated,
LV-GFP treated, Rpe65
 / , and wild-type mice).
Results
LV-RPE65 Allows Efficient and Specific RPE65 Protein
Expression in the Retinal Pigment Epithelium of Rpe65
 / 
Mice
A major concern in gene therapy protocols is to avoid
expression of the therapeutic transgene to nontarget organs
and cells. The Rpe65 gene is expressed mainly in the RPE. To
limit expression of the transgene to this site, we constructed
an HIV-1-derived lentiviral vector known to transduce the
RPE with high efﬁciency when delivered in the subretinal
space and with limited diffusion toward the other retinal
layers [10,24–27]. Furthermore, we used a 0.8 kbp proximal
fragment of the human RPE65 gene (R0.8) with the aim of
driving transgene expression speciﬁcally in RPE cells.
In a ﬁrst series of experiments we characterized the pattern
of transgene expression from the R0.8 promoter in the
lentiviral context (Figure 1). We treated Rpe65
 /  mice by
intravitreal injection at P5 or subretinal injection at 1 mo
with HIV-1-derived lentiviral vectors encoding either the
GFP reporter gene (LV-GFP) or the Rpe65 cDNA (LV-RPE65),
under the control of the R0.8 promoter. In both cases,
immunoﬂuorescence labelling performed 1 wk after gene
transfer revealed GFP (Figure 1A–1D) or RPE65 protein
expression (Figure 1F and 1G) in a large area of the RPE. In
addition, immunolabelling of GFP led to detection of other
cell types in the retina. In some cases, a few photoreceptors
were transduced after intravitreal injection of neonates only
(Figure 1D), as well as occasionally some Mu ¨ller cells in
subretinal injection of adults (Figure 1C). In the latter case,
the transduction of Mu ¨ller cells seemed to be limited to a
lesion of the retina due to the surgical procedure. These
ectopic expressions always accounted for a very low percent-
age of the transduced cells. After LV-RPE65 injections, the
presence of RPE65 protein in the RPE was conﬁrmed by the
use of two different antibodies (see Materials and Methods).
Nevertheless, contrary to what we observed after GFP gene
transfer, we did not detect RPE65 protein in either photo-
receptors or Mu ¨ller cells. This most probably reﬂects the
difference in detection sensitivity between the GFP and the
RPE65 antibodies. These results demonstrate the usefulness
of the lentiviral vector and the R0.8 promoter to re-express
the RPE65 protein in the RPE of RPE65-deﬁcient mice.
Next we undertook a quantitative study to characterize
transgene expression in the RPE at a later time point.
Rpe65
 /  mice at age 5 d received a bilateral injection in the
vitreous of LV-GFP (n ¼ 5) or LV-RPE65 (n ¼ 5) at a dose of
20 ng of p24 (corresponding to 6 3 10
4 transducing units for
the GFP vector), and transgenes expression was analyzed at
the age of 4 mo. Cryostat serial sections were immunola-
belled, and the extent of RPE stained for either GFP or
RPE65 was determined. We used the intersection distance to
deduce the total area of the RPE expressing the respective
transgenes. This quantiﬁcation revealed long-lasting trans-
gene expression. We determined a transduced area of 0.93
6 0.33 mm
2 in the LV-GFP-treated group and of 0.32 6
0.2 mm
2 in the LV-RPE65-treated group. We also observed
signiﬁcant heterogeneity in the extent of the transduced
area within each group. Some eyes displayed transgene
expression spanning a large area of the retina, whereas
others showed only little or no expression. This hetero-
Figure 1. The Lentiviral Backbone Containing the R0.8 Promoter
Fragment Efficiently Expresses a Transgene in the Mouse RPE
Rpe65
 /  mice received the LV-GFP vector (A–D) or the LV-RPE65 vector
(F and G) as an intravitreal injection at P5 (A, D–G) or a subretinal
injection at 1 mo of age (B and C). 1 wk later GFP expression in the RPE
was detected spanning a large proportion of the retina (A and B).
Although to a lesser extent, transduced cells were also evident in the
photoreceptor layer after injection at P5 (D). GFP expression was
detected in the ONL (arrowheads in D) as well as in the outer segments
(arrows in D). (E) DAPI counterstaining of the sample in (D). GFP was also
detected occasionally in Mu ¨ller cells after injection in the subretinal
space at the age of 1 mo (C). After injection of the LV-RPE65 vector,
immunolabelling showed RPE65 expression in the RPE (F and G). (H and
I) Control RPE65 immunolabelling on noninjected Rpe65
 / retina (G) and
wild-type retina (H). Scale bar in (I): 100 lm in A, B, and G–I; 25 lm in C–F.
DOI: 10.1371/journal.pmed.0030347.g001
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which, in our hands, remains highly variable. In summary,
the histological analysis demonstrated long-term (4 mo)
expression of the transgenes in areas of variable size.
Rpe65 Gene Transfer at P5 Restores Retinal Function of
Rpe65
 /  Mice
To reveal whether Rpe65 transgene expression results in an
improvement of retinal function, we recorded the ERG
response in Rpe65
 /  animals 2 mo following vector injection
at P5. In uninjected Rpe65
 /  mice, the ERG recorded in
scotopic conditions was characterized by an increase of the
response threshold (i.e., the retina is less sensitive to light),
when compared to wild-type animals. In line with previous
studies [6], a 3.5 log unit (about 3,000-fold) lower stimulus was
indeed sufﬁcient to elicit in wild-type animals a b-wave of
similar amplitude to the one observed for a stimulus of 3 cd s/
m
2 in Rpe65
 /  mice. Furthermore, in uninjected Rpe65
 / 
mice, we never detected an a-wave (unpublished data).
Similarly, in the LV-GFP treated group, the threshold of the
b-wave appeared for the most intense stimuli, i.e., 3–10 cd s/
m
2, and the a-wave was never detected (Figure 2A, left
tracings). In contrast, the LV-RPE65 treatment improved to a
great extent the b-wave threshold of the Rpe65
 / mice (Figure
2A, right tracings). In this group, the threshold was improved
for 6/10 eyes and, in the best cases (n¼2), the b-wave response
appeared for stimuli as low as 10
 2 cd s/m
2 (i.e., 10-fold less
sensitivity than wild type, compared to the 3,000-fold less
sensitivity of the LV-GFP group) and could reach an
amplitude equivalent to 34.6% of the mean of wild-type
controls (333 6 32.6 lV; n ¼ 12) at the highest stimulus
intensity (25 cd s/m
2). As did the b-wave, an a-wave was clearly
evidenced in the animals showing the best responses, which
reached 23.1% of the wild type mean (128.9 6 15.3 lV; n¼12)
for the 25 cd s/m
2 stimulus. Although the restoration of
retinal function after LV-RPE65 treatment was variable, the
statistical analysis of the b-wave amplitude showed a
signiﬁcant difference between LV-GFP and LV-RPE65 treat-
ments (Figure 2B, p ¼ 0.023 determined by ANOVA for
repeated measures). It is important to note that we have
included in this statistical analysis all the treated animals
without discrimination, i.e., even those for which transgene
expression was low or undetectable (see quantiﬁcation
below).
To assess whether the degree of ERG restoration was
correlated with the size of the RPE area expressing Rpe65
after gene transfer, we attributed a functional score to each
eye. This score was deﬁned as the lowest stimulus intensity
(expressed in log mcd s/m
2) for which a rise of the b-wave was
evident (response threshold), and was plotted as a function of
the area of RPE expressing the transgene (GFP or Rpe65;
Figure 2C). In the LV-GFP group, no b-wave was triggered by
stimuli below 3.5 log mcd s/m
2 regardless of the size of the
Figure 2. The LV-RPE65 Vector Restores the ERG Response of the Rpe65
 /
  Mice
Rpe65
 /  mice were treated P5 by an intravitreal injection of 20 ng of
lentiviral vector.
(A) ERG response to single flashes was recorded in scotopic condition at
2 mo of age. After LV-GFP treatment, the mice showed a response
typical for Rpe65
 /  mice, with the a-wave absent and the b-wave
elicited only for the highest stimuli (i.e., 10 and 25 cd s/m
2; left
tracings). After LV-RPE65 treatment, a stimulus of 10
 2 cd s/m
2 was
sufficient to trigger the b-wave, and the a-wave appeared for a stimulus
of 0.3 cd s/m
2 (right tracings). Vertical bars indicate occurrence of the
stimuli; x-axis: 40 ms/div; y-axis: 100 lV/div.
(B) Summary of the ERG recordings performed 2 mo after vector delivery
at P5 in Rpe65
 /  mice. Amplitude of b-wave (expressed in lV) is
represented for each stimulus intensity. In the LV-RPE65-treated group
(squares), the b-wave rose with a stimulus as low as 10
 2 cd s/m
2, whereas
in the LV-GFP-treated group (triangles) 3 cd s/m
2 were necessary to elicit
the b-wave. ANOVA for repeated measures showed significant stimulus
intensity effect (p , 0.0001), group effect (p ¼ 0.023), and group versus
stimulus intensity interaction (p¼0.002). Data are presented as mean 6
standard error of the mean (SEM).
(C) Improvement of the ERG response after LV-RPE65 treatment is
correlated with the level of RPE65 expression. The area of the retina
expressing GFP (triangles) or RPE65 (squares) was quantified for each eye
at age 4 mo after gene transfer at P5, and plotted against the b-wave
threshold (defined as the intensity of the lowest stimulus capable of
eliciting the b-wave, expressed in log mcd s/m
2).
DOI: 10.1371/journal.pmed.0030347.g002
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Cone Rescue after Gene Transfer for LCAtransduced area (Figure 2C). In contrast, a b-wave was elicited
in some mice of the LV-RPE65 group by stimuli as low as 1 log
mcd s/m
2, the mice displaying the better sensitivity being also
those with the largest transduced area (Figure 2C). This
conﬁrmed that LV-RPE65 treatment restores retinal function
and that the degree of restoration depends on the size of the
transduced area.
LV-RPE65 Treatment Delays Cone Degeneration in
Rpe65
 /  Mice
Previous studies have described cone loss of function and
degeneration in Rpe65
 /  mice as early as at 2 wk of age
[6,17,19,34]. However, cone survival after Rpe65 gene transfer
has not been extensively investigated so far [16,17]. We
therefore analyzed in detail cone morphology and the
expression of cone-speciﬁc markers by quantifying the
expression of different markers at 4 mo of age on sections
adjacent to the one used for quantiﬁcation of GFP and Rpe65
expression (after gene transfer at P5, see above). We ﬁrst
labelled the retinas with PNA, which binds the interphotor-
eceptor matrix sheath surrounding cone outer segments
(Figure 3A and 3B). For each eye, PNA-positive structures
were counted across the entire span of the retina in sections
that cut through the optic nerve head. The optic nerve was
used here as a reference to select a central section on which
to quantify the different markers. This retinal area does not
necessarily correspond to the site of maximal transgene
expression, but, considering that cone markers are subjected
to regional variability, it has the advantage of delimiting a
reproducible area for cell counting. We observed a signiﬁ-
cantly higher number of PNA-labelled structures after LV-
RPE65 treatment (258 6 24, n ¼ 9) compared to LV-GFP
treatment (141 6 10, n ¼ 7, p ¼0.007) or untreated mice (172
6 10, n ¼ 4, p ¼ 0.018). Moreover, the best scores were
obtained in eyes that most widely expressed the Rpe65
transgene as evaluated by the total area of RPE expressing
RPE65 protein (unpublished data) and reached up to 50%
(mean 37% 6 4%, n¼9) of the amount of PNA present in the
wild-type control (Figure 3C). This quantiﬁcation demon-
strated that LV-RPE65 treatment at P5 conserves the
interphotoreceptor matrix sheath of cones for an extended
period of time.
To assess cone survival more speciﬁcally, we used immuno-
ﬂuorescence labelling of the cone-speciﬁc protein transducin
(GNAT2), the mRNA level of which is drastically reduced at 2
mo of age in Rpe65
 /  mice [19]. In wild-type animals, GNAT2
immunolabelling revealed numerous cone outer segments
(Figure 3D), while almost no GNAT2 immunoreactivity was
detectable in the whole retina of Rpe65
 / mice at 4 mo of age
(Figure 3E, asterisk). Treatment of Rpe65
 /  mice with LV-
RPE65, but not with LV-GFP, signiﬁcantly increased the
number of outer segment labelled with GNAT2 (Figure 3F–
3I). Similar to the results obtained for PNA afﬁnity, the best
rescue of GNAT2 labelling was observed in eyes with
widespread Rpe65 expression (unpublished data) and reached
up to 50% (mean 26% 6 9%, n¼6) of the amount of GNAT2
present in the wild-type control. This protective effect of
Rpe65 gene transfer corresponds to a 5-fold increase in
correctly localized GNAT2 labelling compared to untreated
mice (Figure 3F).
All these results represent a mean for the entire section
cutting the optic nerve in the middle, but do not accurately
show regional rescue at the site of transgene expression. To
address this point, we counted the number of GNAT2-
positive outer segments in the RPE region expressing the
Rpe65 transgene on sections double-labelled for GNAT2 and
RPE65 (Figure 3H), and thus established a cone density
expressed as cell number per millimeter of epithelium. We
found similar numbers of cones labelled for GNAT2 per
millimeter for both LV-RPE65 (154 6 29 cells/mm, n¼4) and
wild-type controls (143 6 12 cells/mm, n ¼ 4). Finally, we
noted that the area of GNAT2 staining (i.e., cone rescue) was
larger than the area with detectable RPE65 expression. We
measured the length of the transitional area (the area with
GNAT2-positive cells but without RPE65 expression, Figure
3J, dashed line). Assuming that the transduced area is circular
(Figure 3K), we determined its radius (‘‘x’’ in Figure 3K) and
found a linear correlation (Figure 3L) with the width of
transitional area (‘‘y’’ in Figure 3K). In summary, injection of
the LV-RPE65 vector at P5 leads to correct GNAT2
expression in Rpe65
 /  mice even 4 mo after the treatment
not only at the site of transgene expression but in the
surrounding area as well.
Two other cone markers that are important for cone
function are S- and M/L-opsin. Both of these opsins are
thought to be expressed in different proportions in the same
cell, thus determining the precise photoreceptor type of the
cell, i.e., blue cone (predominant S-opsin expression) or red/
green cone (predominant M/L-opsin expression) [35]. It has
been shown that expression of these opsins is reduced and
thatthe remaining proteinsare mislocalized in Rpe65
 / /Rho
 / 
double knockout mice as early as P25, identifying 11-cis-
retinal as a key partner for correct cone opsin trafﬁcking [18].
In light of this information, we analysed the effect of LV-
RPE65 treatment on the amount and distribution of the two
cone opsins (Figure 4). In the wild-type retina, the S-opsin and
M/L-opsin antibodies strongly labelled the outer segments of
different or common subsets of cones with a gradient of
expression leading to a predominantly dorsal expression of
the M/L-opsin and a predominantly ventral expression of the
S-opsin (Figure 4A). In Rpe65
 /  mice, a marked decrease in
both the M/L-opsin and the S-opsin was noticed with rare
labelling showing mostly mislocalized proteins (unpublished
data). Similarly, in LV-GFP-treated mice, the rare and weak
staining present at this age was mostly mislocalized in the
cellular body (Figure 4E and 4F). After LV-RPE65 treatment,
we observed an increase in expression of both opsins, which
had adopted the correct cellular localization in the outer
segments (Figure 4B and 4D). We compared the three eyes
showing maximal transgene expression for each group (as
determined by the RPE layer area expressing GFP or RPE65)
and obtained a signiﬁcant improvement of both S- and M/L-
opsin expression in LV-RPE65-treated animals (respectively,
on average 39% 6 5% and 38% 6 9% of the wild-type
amount) compared to LV-GFP treated (respectively, on
average 3% 6 1.5% and 9% 6 2.3% of the wild-type amount)
or untreated knockout (respectively, on average 4% 6 1%
and 18% 6 1.4% of the wild-type amount) (Figure 4G). Using
the same methodology as for GNAT2 staining, we also
quantiﬁed the extent of the transitional area on sections
double labelled for RPE65 and S-opsin (n ¼ 5). Similar to the
quantiﬁcation of GNAT2 transitional area depicted in Figure
3L, we found a strong correlation between the radius of the
transduced area and the extent of the transitional area
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2¼
0.988).
In summary, we show that 4 mo after LV-RPE65 treatment
at P5 there is a signiﬁcant increase in cone sheath labelling by
PNA and an increased expression of the three cone-speciﬁc
markers GNAT2 and S- and M/L-opsin. These results indicate
prolonged cone survival due to the restoration of RPE65
activity. Moreover, analysis of cone density in terms of RPE65
expression shows a transitional area where the therapeutic
transgene is not detectable but cones are still spared.
Figure 3. PNA and GNAT2 Labelling Increase after LV-RPE65 Treatment at P5 of Rpe65
 /  Mice
(A and B) PNA linked to TRITC labels cone outer segments in red in a LV-RPE65-treated eye (A). (B) Merged picture representing RPE65 (green), PNA
labelling (red), and cell nuclei (blue) in the same section used in (A).
(C) PNA labelling was quantified by counting the number of PNA-positive outer segments in the sagittal section that bisected the optic nerve for each
eye of LV-RPE65 (n ¼ 9) or LV-GFP (n ¼ 7) treated groups as well as of Rpe65
 /  (KO; n ¼ 4) and wild-type control groups (n ¼ 4). Values represent
percentage of wild type (set to 100%). A significant increase of PNA labelling was seen for LV-RPE65 treated group compared to the LV-GFP (n¼7, p¼
0.007) or untreated (n ¼ 4, p ¼ 0.018) groups (*p , 0.05). Data are presented as a mean percentage of the wild-type value 6 SEM.
(D) GNAT2 (revealed in green by a secondary antibody linked to FITC) in a wild-type retina.
(E) The GNAT2 staining is extremely weak in Rpe65
 / mice at age 4 mo. *Example of remaining outer segment staining counted in the Rpe65
 / and LV-
GFP treated groups.
(F) Quantification of GNAT2 labelling was performed (as described for PNA labelling) and showed a significant increase of GNAT2 expression in the LV-
RPE65 group (n¼6) compared to the LV-GFP (n¼8, p¼0.017) or untreated (n¼4, p¼0.03) groups (*p , 0.05). The discrepancy in cone loss between
PNA and GNAT2 markers in Rpe65
 /  (compare control groups in C and F) is most probably due to the persistence of the cone interphotoreceptor
matrix sheath, which can still be present after other cone markers have disappeared [42]. Data are presented as a mean percentage of the wild-type
value 6 SEM.
(G and H) A GNAT2 pattern similar to that observed in wild-type mice is recovered after LV-RPE65 treatment in Rpe65
 /  mice (G). Double labelling
shows GNAT2 stained in red, RPE65 in green (H). Example of outer segment positive for GNAT2 is pointed by an arrowhead.
(I) LV-GFP treatment does not improve GNAT2 expression in Rpe65
 / . Example of weak residual labelling for GNAT2 in a control eye treated with LV-
GFP (arrow).
(J) After LV-RPE65 treatment, a transitional area with spared GNAT2-positive cones but devoid of RPE65 expression was observed (dashed line).
(K and L) In (K) the diagram depicts a transitional area in a ring (red) surrounding the transduced area (green). The radius of the transduced area is
indicated by x; the width of the transitional area is indicated by y. The relation of x to y is graphed in (L); the radius of the transduced area is linearly
correlated with the transitional area.
Scale bar in (I): 50 lm in A, B, E, and G–I; 100 lm in D and J. KO, Rpe65
 /  mice; LV-GFP, LV-GFP-treated mice; LV-RPE65, LV-RPE65-treated mice; WT,
Rpe65
þ/þ mice.
DOI: 10.1371/journal.pmed.0030347.g003
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for Rpe65 Gene Transfer
In utero rAAV-mediated Rpe65 gene transfer in Rpe65
 / 
mice led to an improvement of the ERG [16], but the same type
of vector failed to substantially restore retinal function when
administered at 3 wk of age [17]. These studies indicate that
there might be a small therapeutic window during which
treatment outcome is optimal. To determine the ideal time
point for lentivirus-mediated Rpe65 gene transfer in Rpe65
 / 
mice, we injected lentiviral vectors in an additional group of
mice at 1 mo of age. ERG responses were recorded 1 mo after
injection (i.e., at 2 mo, the same age as for P5-treated animals).
LV-RPE65 treatment at 1 mo increased retinal sensitivity (b-
wave threshold) by 2 log units in comparison to LV-GFP-
treated or untreated Rpe65
 / animals (Figure 5A). To identify
whether this functional rescue reﬂects an improved cone
survival, we studied cone rescue using PNA labelling and
GNAT2 immunoﬂuorescence after sacriﬁce of these mice at 3
mo of age. For both markers, we observed no improvement
related to LV-RPE65 treatment (Figure 5B). In fact, the level of
GNAT2-positive cells after LV-RPE65 treatment was 3% 6
1% of the wild-type GNAT2 amount, in the same range as for
LV-GFP treated or untreated Rpe65
 / mice (Figure 5B). Thus,
despite successful transduction of the RPE and improvement
in the overall retinal sensitivity, cones were not rescued when
mice were treated at 1 mo of age. These results clearly indicate
that early cone loss [18,19] is irreversible and can be prevented
only by early treatment (e.g., at P5, as described above).
The vector dose is a second issue that is critical in view of a
clinical application. To explore the importance of this
parameter, we treated Rpe65
 /  mice at P5 with a 9-fold
higher dose of LV-RPE65 vector than in the previous
experiments, i.e., 180 ng of p24 (corresponding to 5.5 3 10
5
transducing units for the LV-GFP vector). In this case, we
recorded the ERG after 1 mo, and we again observed
heterogeneity in the improvement of the response after
Rpe65 gene transfer, but we also found animals with a ‘‘near-
normal’’ ERG response characterized by a threshold of 10 
3
cd s/m
2, similar to wild-type animals (n ¼ 3 eyes). In these
animals, a-wave and b-wave amplitudes reached, respectively,
43.8% and 70% of the wild-type control means for the
highest stimulus intensity (25 cd s/m
2; Figure 6A, left tracings).
Moreover, for the stimulus at which the ERG response
reached a plateau (10 cd s/m
2), we observed a higher b-wave
amplitude after treatment with a high dose of the LV-RPE65
vector (119.2 6 23 lV, n ¼ 6) than after treatment with a low
dose (69.6 6 12.9 lV, n¼8, p¼0.032 determined by Student’s
t-test). ERG responses in animals treated with a high dose of
LV-GFP vector (n ¼ 6, unpublished data) were indistinguish-
Figure 4. S- and M/L-Cone Opsin Labelling Increased after LV-RPE65 Treatment of Rpe65
 /  Mice at P5
(A) Double immunostaining of wild-type retina with antibodies directed against S-opsin (red) and M/L-opsin (green) localized in the outer segment.
Note that some cones express both opsins while others are mainly labelled for only one of these opsins.
(B–D) LV-RPE65 treatment allows similar expression of both S- and M/L-opsin to the wild-type retina in the region expressing the Rpe65 transgene.
Arrows indicate double labelling of cone opsins; arrowheads indicate cone stained only for S-opsin.
(E and F) LV-GFP treatment does not rescue S- or M/L-opsin expression and shows a pattern of staining similar to untreated Rpe65
 /  (unpublished
data). *Mislocalized and reduced S- and M/L-opsin expression.
(G) Quantification of the three eyes with the highest transgene expression for LV-RPE65 and LV-GFP groups shows a significant increase in both S- and
M/L-opsin expression after LV-RPE65 treatment compared to the LV-GFP (p¼0.005 for M/L-opsin and p , 0.0001 for S-opsin) or untreated (n¼4, p¼
0.024 for M/L-opsin and p , 0.0001 for S-opsin) groups (*p , 0.05). No statistical difference was noted between LV-GFP and untreated knockout animals.
Data are presented as mean 6 SEM. Scale bar in (F): 500 lmi nA ;5 0lm in B–F. KO, Rpe65
 /  mice; LV-GFP, LV-GFP-treated mice; LV-RPE65, LV-RPE65-
treated mice; WT, Rpe65
þ/þ mice.
DOI: 10.1371/journal.pmed.0030347.g004
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Cone Rescue after Gene Transfer for LCAable from untreated knockouts or animals treated with the
low dose of LV-GFP vector (Figure 2A). This experiment
suggests that the level of functional rescue in Rpe65
 /  mice is
improved by a higher dose of lentiviral vector.
LV-RPE65 Treatment Restores Cone Function in RPE65-
Deficient Mice
As rod and cone activity in Rpe65
 /  mice cannot be readily
distinguished with ERG recordings [6], we used an additional
transgenic mouse line to prove that LV-RPE65 treatment
rescues cone function. Mice lacking the rod transducin alpha
subunit (Gnat1a
 / ) [36] were crossed with Rpe65
 /  mice to
obtain Rpe65
 / /Gnat1a
 /  double knockout mice. In these
mice, any retinal response to light after 11-cis-retinal supplied
through Rpe65 gene transfer cannot be derived from the rod
transduction cascade, which is disrupted [32]. Similar to the
previous experiment, we treated double knockout mice at P5
by intravitreal injection of LV-RPE65 (n ¼ 5) or LV-GFP (n ¼
5) with 180 ng of p24 capsid protein, and we measured the
ERG response after 1 mo. In the LV-GFP-treated group, we
were not able to detect an ERG response to any stimulus
intensity (Figure 6B, left tracings), similar to what is observed
in untreated mice (unpublished data). In contrast, LV-RPE65
treatment of Rpe65
 / /Gnat1a
 /  mice restored an ERG
response typical of cones, rising for the high-intensity stimuli
and showing a bell-shaped curve (Figure 6B, right tracings).
Furthermore, a response was also clearly detected when the
ERG was recorded in photopic conditions (Figure 6C, right
tracings). This, together with the fact that the rods of these
mice are unable to function, demonstrates that lentivirus-
mediated transfer of the Rpe65 gene is able to rescue a
functional response originating from the cones in a model of
complete chromophore deprivation, the Rpe65
 /  mouse.
Discussion
We report a successful restoration of retinal function by
lentivirus-mediated Rpe65 gene transfer in an animal model
of LCA. Furthermore, the rescue of the retinal function
assessed by ERG is the best ever reported in the Rpe65
 / 
mouse model of LCA in terms of cone protection and visual
sensitivity restoration [16,17], demonstrating the potential of
this vector for a clinical application. In addition, we
demonstrated that the use of the R0.8 promoter allows
long-lasting expression of the Rpe65 transgene mostly
restricted to RPE cells. From a clinical perspective, preser-
vation of cone vision is a critical endpoint—indeed is the ﬁnal
goal for human therapies. We demonstrate, using different
markers speciﬁc for cones, that Rpe65 gene transfer led to
preservation of cone morphology and, in a transgenic line
deﬁcient for both RPE65 and the rod phototransduction
cascade (Gnat1a
 / ), to restoration of cone function. The
absence of ERG response in untreated or LV-GFP-treated
Rpe65
 / /Gnat1a
 /  mice (Figure 6B and 6C), together with the
fact that the residual response in Rpe65 knockout animals
originates from rods [6], indicate that the rod response is
abolished in this mouse strain due to the knockout of the
Gnat1a gene. The ERG response restoration after LV-RPE65
treatment of the double-knockout animals thus demonstrates
that Rpe65 gene transfer elicits a functional response from
cone photoreceptors in the Rpe65
 /  genetic background
(Figure 6B and 6C).
As gene therapy trials for RPE65 deﬁciencies are on the
verge of starting, it is important to accumulate data on
different preclinical models using various vectors. The value
of our results is reinforced by the fact that cone degeneration
in Rpe65
 / mice starts just 2 wk after birth [18,19]. As a result,
cone function is almost not recordable at P25 [18] and is
completely lost by 4–5 wk of age [6]. Accordingly, we show
here that LV-RPE65 prolongs cone survival for a protracted
period (at least 4 mo, the latest time point studied) when
administered at P5, but not at all when applied at 4–5 wk of
age. These results are consistent with previous studies using
rAAV in Rpe65
 /  mice. Dejneka et al. found in utero
treatment to be more efﬁcient than treatment of adult mice
(1 or 2.5 mo), but cone function and survival were not
determined in this report [16]. In another study, by Lai et al.,
in mice injected at age 3 wk only 50% of the density of S-
opsin labelling was restored at the site of injection at 8 mo
[17]—consistent with our results showing that gene therapy
given at 1 mo does not protect cones compared to that given
at P5. Thus, the degeneration of cones beginning at age 2 wk
[19] is irreversible, but can be prevented by early restoration
of RPE65 activity (present study) or exogenous 11-cis-retinal
[18]. Lentivirus-mediated gene transfer at P5 seems indeed
optimal for cone protection in Rpe65
 /  mice.
Consistent with the ability of lentiviral vectors to provide
long-lasting expression in various cells and tissues in vitro as
well as in vivo, and in the eye in particular [10,11], we
observed long-term restoration of RPE function and preser-
vation of cone photoreceptors, lasting at least 4 mo after gene
transfer, the latest time point studied. Furthermore, pheno-
typic classiﬁcation of LCA cases in humans placed RPE65
Figure 5. Rpe65 Gene Transfer Performed at 1 mo Fails to Protect Cone
Photoreceptors from Degeneration
Rpe65
 /  mice were treated by subretinal injection at age 1 mo with 20
ng of lentiviral vector. Treatment at this age with the LV-RPE65 vector
restored ERG response with a threshold response of 3310
 2 cd s/m
2 for
the b-wave (A), whereas no improvement was observed in the LV-GFP
treated group (unpublished data). (B) Counting of PNA-positive and
GNAT2-positive cells revealed that Rpe65 gene transfer performed at age
1 mo was unable to protect the cones from degeneration. Data are
presented as mean 6 SEM.
DOI: 10.1371/journal.pmed.0030347.g005
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Cone Rescue after Gene Transfer for LCAdeﬁciencies in the rod-cone dystrophies group [8,37,38]. This
classiﬁcation suggests that, to act on cone function, which is
the main therapeutic target to restore high-acuity vision for
the patient, the intervention window will be proportionally
even longer in human patients than in Rpe65
 /  mice. Our
results thus support a potential clinical application of RPE65
gene transfer in humans.
For clinical trials it is also important to deﬁne accurately
the vector dose that elicits a satisfactory therapeutic effect
without triggering side effects. In the present study we show
that a low virus dose restores a ‘‘near-normal’’ retinal
sensitivity (Figure 2B) and completely blocks cone degener-
ation in the area expressing the therapeutic transgene, as well
as in the vicinity of the treated area. Our study suggests that
increasing the vector dose leads to an improvement of the
ERG rescue (Figure 6A), but surgical limitations in mice
resulted in the suggestion that increasing the vector dose
leads to a higher level of expression in the transduced area
rather to an expansion of the transduced area. The area of
transgene expression might also be a critical parameter for
effective ERG rescue: Above a certain threshold, retinal
sensitivity is greatly enhanced (Figure 2C). Furthermore, the
size of the transduced area is linearly correlated with the
extent of cone survival area (Figure 3L), which exceeds the
area of therapeutic transgene expression (Figure 3J). One
explanation of this phenomenon could be heterogeneity in
transduction efﬁciency within the injected area, the centre
being highly transduced while the periphery expresses the
transgene at a lower level (undetectable, but functionally
relevant). Nevertheless, we never observed such heterogeneity
after GFP or Rpe65 gene transfer, and it has, to our
knowledge, never been reported after subretinal injection
of a gene transfer vector. Another possible explanation is that
lateral diffusion of 11-cis-retinal promotes cone survival also
around the actually transduced area. Local concentration
(and thus diffusion) of the chromophore should increase with
the size of the transduced area, explaining the linear
relationship between the sizes of respectively transduced
area and cone survival area (Figure 3L). This would imply
that, in Rpe65
 /  mice, cone survival depends more on the
availability of a certain amount of the chromophore than on
a restoration of the RPE65 function in the adjacent RPE cell.
This hypothesis is reinforced by the observation that
exogenously supplied chromophore protects cones until at
least P25 in RPE65-deﬁcient mice [18]. However, the exact
mechanism underlying cone rescue following Rpe65 gene
transfer is still unknown, and we cannot exclude an indirect
effect resulting, for example, from the participation of the
Mu ¨ller cells in the regeneration of cone pigments.
The strong correlation between the size of the actually
transduced area and the size of the cone survival area is a
critical point with regard to the treatment of patients. It may
help to determine precisely the retinal region to be treated to
reach a therapeutic level of 11-cis-retinal at the site of the
fovea. To rescue high-acuity vision in human patients, it
might thus be sufﬁcient to target the vicinity of the fovea with
a limited dose of vector. Such treatment would be achieved
most efﬁciently by subretinal injection, a procedure already
used for conventional drug delivery [39], and proposed for
gene therapy clinical trials (US clinical trials 0410–677 and
0510–740; available at: http://www.gemcris.od.nih.gov/). Fur-
thermore, from a clinical perspective, the existence of a
Figure 6. High Dose of LV-RPE65 Vector Restores a ‘‘Near Normal’’ ERG Response in Rpe65
 /  Mice and Rescues the Activity of Cone Photoreceptors in
Rpe65
 / /Gnat1a
 /  Mice
(A) Scotopic ERG recorded at age 1 mo of a Rpe65
 /  mouse treated at P5 with 180 ng of LV-RPE65 (left tracings) and of a Rpe65
þ/þ untreated mouse
(WT, right tracings). At this dose, LV-RPE65 treatment restored an ERG response similar to a wild-type response. For Rpe65
 /  eyes showing the best
restoration (n ¼ 3), thresholds of both the a-wave and the b-wave reached normal levels with, respectively, 10 
1 and 10 
3 cd s/m
2.
(B and C) At P5 Rpe65
 / /Gnat1a
 /  mice received a bilateral intravitreal injection of the vector (LV-RPE65 or LV-GFP) at a dose of 180 ng of p24 capsid
protein. 1 mo later, the ERG was recorded in scotopic (B) and in photopic conditions (C). Vertical bars indicate occurrence of the stimuli; x-axis: 40 ms/
div; y-axis: 100 lV/div (left tracings), except right tracings in (A) (200 lV/div).
DOI: 10.1371/journal.pmed.0030347.g006
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Cone Rescue after Gene Transfer for LCAtransitional area where cones are rescued but transgene not
expressed in RPE cells, is of prime importance to increase the
safety of the procedure and optimize the restoration of the
biological function. This could indeed allow for a therapeutic
effect at the fovea without direct treatment of this zone, a
crucial advantage in terms of surgical risk.
Using a rodent model of LCA, we show the potential of
lentiviral vectors to efﬁciently restore a deﬁcient function by
speciﬁc gene transfer to the RPE. A recent study published by
Yanez-Munoz et al. (2006) demonstrates that an integration-
deﬁcient lentiviral vector is as efﬁcient as an integration-
proﬁcient vector for delivery of Rpe65 in another model of
LCA, the Rpe65
rd12/rd12 mouse [40]. These new in vivo data
obtained with a vector minimizing mutagenesis risks by
avoiding integration into the host genome reinforce our
results that propose the lentiviral vector as an alternative for
patient treatment. Moreover, it is important to note that
stable and efﬁcient retinal gene transfer by lentiviral vectors
has already been documented in a nonhuman primate model
[41], rendering this family of vectors very attractive for retinal
applications targeting the retina. The next step toward a
clinical application is to validate the use of classical lentiviral
vectors, or of their integration-deﬁcient version, using larger
models such as RPE65-deﬁcient dogs, and to analyze precisely
the long-term efﬁciency of lentivirus-mediated RPE65 gene
transfer in an eye similar in size to the human one. These
studies should determine if the lentiviral vector could
represent an alternative to rAAV for gene transfer into the
RPE.
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Editors’ Summary
Background. Leber congenital amaurosis (LCA) is the name of a group
of hereditary diseases that cause blindness in infants and children.
Changes in any one of a number of different genes can cause the
blindness, which affects vision starting at birth or soon after. The
condition was first described by a German doctor, Theodore Leber, in the
19th century, hence the first part of the name; ‘‘amaurosis’’ is another
word for blindness. Mutations in one gene called retinal pigment
epithelium-specific protein, 65 kDa (RPE65)—so called because it is
expressed in the pigment epithelium, a cell layer adjacent to the light-
sensitive cells, and is 65 kilodaltons in size—cause about 10% of cases of
LCA. The product of this gene is essential for the recycling of a substance
called 11-cis-retinal, which is necessary for the light-sensitive rods and
cones of the retina to capture light. If the gene is abnormal, the
sensitivity of the retina to light is drastically reduced, but it also leads to
damage to the light-sensitive cells themselves.
Why Was This Study Done? Potentially, eyes diseases such as this one
could be treated by gene therapy, which works by replacing a defective
gene with a normal functional one, usually by putting a copy of the
normal gene into a harmless virus and injecting it into the affected
tissue—in this case, the eye. The researchers here wanted to see whether
expressing wild-type RPE65 using a particular type of gene vector that
can carry large pieces of DNA transcript—a lentiviral vector—could
prevent degeneration of cone cells and restore cone function in a mouse
model of this type of LCA—mice who had had this Rpe65 gene
genetically removed.
What Did the Researchers Do and Find? Injection of the normal gene
into the retina of Rpe65-deficient mice led to sustained expression of the
protein RPE65 in the retinal pigment epithelium. Electrical recordings of
the activity of the eyes in these mice showed that Rpe65 gene transfer
restored retinal function to a near-normal level. In addition, Rpe65 gene
transfer completely prevented cone degeneration until at least four
months, an age at which almost all cones have degenerated in the
untreated Rpe65-deficient mice.
What Do These Findings Mean? These findings suggest that it is
theoretically possible to treat this type of blindness by gene therapy.
However, because this study was done in mice, many other steps need
to be taken before it will be clear whether the treatment could work in
humans. These steps include a demonstration that the virus is safe in
humans, and experiments to determine what dose of virus would be
needed and how long the effects of the treatment would last. Another
question is whether it would be necessary (or even possible) to treat
affected children during early childhood or when children start losing
vision.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030347.
  The Foundation for Retinal Research has detailed information on
Leber’s congenital amaurosis
  Contact a Family is a UK organization that aims to put families of
children with illnesses in touch with each other
  The Foundation for Fighting Blindness funds research into, and
provides information about many types of blindness, including
Leber’s congenital amaurosis
  This Web site provides information on gene therapy clinical trials,
including those dedicated to cure eye diseases
  This foundation provides information on diseases leading to blindness,
including Leber’s congenital amaurosis
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Cone Rescue after Gene Transfer for LCA